Clinical Trial Update: Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension. [Phase 3]

View source ↗

Summary

Phase 3 trial of a buprenorphine transdermal patch in osteoarthritis patients requiring opioids was terminated, with a 52-week safety extension and results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• Buprenorphine transdermal patch (buprenorphine)

Snippet

Sponsor: Purdue Pharma LP | Conditions: Osteoarthritis | Phase 3 | Status: TERMINATED | Results posted: 2010-09-23